IVISense™ Annexin-V 750 fluorescent imaging probe (Annexin-Vivo™) is designed to enable in vivo visualization and quantification of membrane-bound phosphatidylserine (PS) during the early stages of apoptosis.
For research use only. Not for use in diagnostic procedures.
. false false
Annexin A5 (Annexin V) is a cellular protein in the annexin group. Annexin V is a probe commonly used to detect apoptotic cells by its ability to bind to phosphatidylserine, a marker of apoptosis when it is on the outer leaflet of the plasma membrane.
IVISense Annexin-V 750 is a targeted fluorescent imaging agent comprising the selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. IVISense Annexin-V 750 enables in vivo visualization and quantification of the membrane-bound phospholipid, phosphotidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.
| 熒光劑類型 | Targeted |
|---|---|
| 光學成像分類 | Fluorescence Imaging |
| 產品品牌名稱 | IVISense |
| 包裝量 | 1.0 Units |
| 運輸條件 | 藍冰 |
| 治療領域 | Atherosclerosis, Oncology/Cancer |
| 產品尺寸 | 1 Vial (10 doses) |
| 波長 | 750 nm |
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Our comprehensive range of bioluminescent and fluorescent imaging reagents provide researchers with the necessary tools to better understand early disease-related biological changes, track disease progression, help guide the drug discovery process, and evaluate efficacy and safety of drug candida ...
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best p ...
Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed usin ...
Protocol for Annexin-Vivo 750 In Vivo Fluorescent Imaging Agent
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
Non-alcoholic fatty liver disease (NAFLD) describes a progressive pathology that affects the liver. Fat accumulation causes fatty liver (NAFL) or steatosis to develop, which leads to lipotoxicity and in turn induces liver inflammation and apoptosis, resulting in non-alcoholic steatohepatitis (NAS ...
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more impo ...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...
